The estimated Net Worth of Mark J Alles is at least $28.4 Milione dollars as of 16 September 2023. Mr. Alles owns over 2,666 units of Syros Pharmaceuticals stock worth over $5,902 and over the last 13 years he sold SYRS stock worth over $28,263,015. In addition, he makes $161,535 as Independent Director at Syros Pharmaceuticals.
Sign up
Mr. Alles SYRS stock SEC Form 4 insiders trading
Mark has made over 43 trades of the Syros Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 2,666 units of SYRS stock worth $4,292 on 16 September 2023.
The largest trade he's ever made was selling 117,099 units of Syros Pharmaceuticals stock on 6 February 2015 worth over $14,131,507. On average, Mark trades about 6,604 units every 28 days since 2012. As of 16 September 2023 he still owns at least 3,666 units of Syros Pharmaceuticals stock.
You can see the complete history of Mr. Alles stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Alles biography
Mark J. Alles serves as Independent Director of the Company. Mr. Alles served as chairman and chief executive officer of Celgene Corporation, a global biopharmaceutical company, from March 2016 until its acquisition by Bristol-Myers Squibb Company in November 2019. Prior to this role, Mr. Alles served as Celgene’s president and chief operating officer from August 2014 to February 2016 and as its chief commercial officer and executive vice president, hematology & oncology from December 2012 to July 2014. Mr. Alles joined Celgene in April 2004. Before joining Celgene, he served in senior commercial management roles at Aventis Pharmaceuticals Inc. (Rhône-Poulenc Rorer) from 1993 to 2004. Mr. Alles received B.S. degree from Lock Haven University of Pennsylvania and served as a Captain in the United States Marine Corps.
What is the salary of Mark Alles?
As the Independent Director of Syros Pharmaceuticals, the total compensation of Mark Alles at Syros Pharmaceuticals is $161,535. There are 11 executives at Syros Pharmaceuticals getting paid more, with Nancy Simonian having the highest compensation of $3,614,020.
How old is Mark Alles?
Mark Alles is 61, he's been the Independent Director of Syros Pharmaceuticals since 2019. There are 8 older and 11 younger executives at Syros Pharmaceuticals. The oldest executive at Syros Pharmaceuticals Inc. is Phillip Sharp, 75, who is the Independent Director.
What's Mark Alles's mailing address?
Mark's mailing address filed with the SEC is C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE, MA, 02140.
Insiders trading at Syros Pharmaceuticals
Over the last 8 years, insiders at Syros Pharmaceuticals have traded over $8,259,551 worth of Syros Pharmaceuticals stock and bought 5,052,185 units worth $51,830,966 . The most active insiders traders include Group, Llc Green Jeremy Red..., Srinivas Akkaraju e Stephane Bancel. On average, Syros Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $135,148. The most recent stock trade was executed by Richard A Young on 28 June 2024, trading 34,837 units of SYRS stock currently worth $178,365.
What does Syros Pharmaceuticals do?
syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
What does Syros Pharmaceuticals's logo look like?
Complete history of Mr. Alles stock trades at Biomarin Pharmaceutical, Syros Pharmaceuticals e Turning Point Therapeutics Inc
Syros Pharmaceuticals executives and stock owners
Syros Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Nancy Simonian,
President, Chief Executive Officer, Director -
Joseph Ferra,
Chief Financial Officer -
Jeremy Springhorn,
Chief Business Officer -
David Roth,
Chief Medical Officer -
Eric Olson,
Chief Scientific Officer -
Gerald Quirk,
Chief Legal & Administrative Officer -
Dr. Nancy A. Simonian M.D.,
Pres, CEO & Director -
Dr. David A. Roth,
Chief Medical Officer -
Dr. Eric R. Olson,
Chief Scientific Officer -
Richard Young,
Director -
Dr. Richard A. Young Ph.D.,
Scientific Founder, Member of Scientific Advisory Board & Director -
Mark Alles,
Independent Director -
Peter Wirth,
Independent Chairman of the Board -
Marsha Fanucci,
Independent Director -
Amir Nashat,
Independent Director -
Phillip Sharp,
Independent Director -
Srinivas Akkaraju,
Independent Director -
Hannah Deresiewicz,
IR Contact Officer -
S. Gail Eckhardt,
Director -
Dr. Christian C. Fritz Ph.D.,
Head of Biology -
Naomi Aoki,
VP of Corp. Communications & Investor Relations -
Gerald E. Quirk,
Chief Operations Officer & Sec. -
Jason Haas,
Chief Financial Officer -
Dr. Nathanael S. Gray Ph.D.,
Scientific Founder & Member of Scientific Advisory Board -
Dr. James E. Bradner M.D.,
Founder -
Alice Tsang Shaw,
Director -
Ventures Fund Iv, L.P.Flags...,
-
Sanj K Patel,
Director -
Vicki L Sato,
Director -
Michael W Bonney,
Director -
Colleen Elizabeth De Simone,
Principal Accounting Officer -
Robert Nelsen,
Director -
Venture Fund Vii, L.P.Arch ...,
-
Kyle D. Kuvalanka,
Chief Operating Officer -
Stephane Bancel,
Director -
Management Co. Vii, L.L.C.P...,
-
Pharm Tech Healthcare Fund ...,
10% owner -
Group, Llc Green Jeremy Red...,
-
Venture Fund Vii Lparch Ven...,
-
Healthcare Ventures Ii, L.P...,
10% owner -
James E Deerfield Mgmt L.P....,
-
Kristin Stephens,
Chief Development Officer -
Deborah Dunsire,
-
Jason Haas,
Chief Financial Officer -
Timothy Tyson,
-
Conley Chee,
President & CEO -
Andrew M. Oh,